$TSOI Therapeutic Solutions International, Inc. Reports

New Post Public Reply Private Reply Replies (0) Message Board
stock-scamper
286
$TSOI Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months


OCEANSIDE, CA -- August 29, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) reported that its second-quarter 2019 revenues rose 1,000% percent for the first 6-month period as compared to the same period in 2018.

These increases were due primarily to the commercialization of NanoStilbene and releasing it for sale after completing our clinical program that included a pharmacokinetic trial and a pilot cancer study in advanced cancer patients using 300mg of nanoparticle pterostilbene. The results of this clinical trial have been submitted to a medical journal for peer review and ultimately for final publication. This represented 4 years of work to develop, patent, manufacture, test, and publish the results of this study which showed a substantial increase in activity of T cells and NK cells as a result of treatment with NanoStilbene.

It is known that NK cells, termed natural killer cells, are the first line of defense against cancer, while T cells provide immunological memory that prevents cancer from coming back. Mechanistically, the authors believed that an increase in immune response was the result of immune suppression in cancer-associated inflammation by NanoStilbene™ [1]. The active ingredient in NanoStilbene™, called pterostilbene, is a potent inhibitor of inflammation and this study gives clear evidence.

We anticipate that when these results are published and made public our sales will increase substantially. NanoStilbene is a very cost-effective nutraceutical adjuvant that has now been shown clinically to be safe and effective at reducing inflammation caused by cancers and at the same time increasing the immune system's ability to fight cancer on its own by way of NK cell population increase.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.

[1] https://mynanostilbene.com

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

CONTACT INFORMATION

Therapeutic Solutions International, Inc.
ir@tsoimail.com
Therapeutic Solutions International, Inc. (PC) (USOTC:TSOI)
Historical Stock Chart
1 Year : From Aug 2018 to Aug 2019

Click Here for more Therapeutic Solutions International, Inc. (PC) Charts.
Therapeutic Solutions International, Inc. (PC) (USOTC:TSOI)
Intraday Stock Chart
Today : Thursday 29 August 2019

Click Here for more Therapeutic Solutions International, Inc. (PC) Charts.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Concerns Rise Over Trump's Cryptocurrency Reserve Strategy

Updated Category News Views 192

Concerns About Cryptocurrency Announcements Prominent economist and market commentator Peter Schiff has urged a Congressional investigation into President Donald Trump's recent foray into cryptocurrency, suggesting that these announcements may involve insider trading and market manipulation. The Key Questions Raised In a recent post on X, Schiff sought answers to several...

Continue Reading
BriaCell Joins Prestigious Program to Boost Cancer Treatments

Updated Category News Views 145

BriaCell Enters MSK’s 2025 Therapeutics Accelerator Program BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, TSX: BCT) is thrilled to share the news of its selection into the Memorial Sloan Kettering Cancer Center (MSK) Therapeutics Accelerator Program for 2025. This prestigious program is designed to fast-track the clinical development of many innovative cancer...

Continue Reading
Exploring Current Net Asset Values of WisdomTree Funds

Updated Category News Views 114

Understanding Net Asset Value (NAV) in Investment Funds Net Asset Value (NAV) is a crucial metric for evaluating the performance of investment funds, representing the value of a fund's assets minus its liabilities. It's important for investors to keep track of NAV as it aids in making informed decisions regarding their investments. Here, we delve into the recent NAVs of...

Continue Reading
DoorDash's Innovative Tools Transforming Restaurant Dynamics

Updated Category News Views 208

Introduction to DoorDash's Expansion DoorDash (NASDAQ: DASH) has recently unveiled exciting developments regarding its Commerce Platform. This significant enhancement is set to assist restaurants in boosting direct sales while fostering better customer relationships across multiple channels. New Features for Restaurant Success The introduced tools are designed to uplift...

Continue Reading
Mezzion's Udenafil Shows Promise in ADPKD Study

Updated Category News Views 34

Positive News for Udenafil in Kidney Disease New updates from Mezzion Pharma Co., Ltd. have come across quite promising. They've reported some favorable results in a preclinical study of udenafil, targeting autosomal dominant polycystic kidney disease (ADPKD). It appears that this PDE5 inhibitor, typically used in aiding cardiovascular issues, now shows potential in...

Continue Reading